Percutaneous sirolimus ( DrugBank: Sirolimus )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 278 | Huge lymphatic malformation with cervicofacial lesion | 1 |
278. Huge lymphatic malformation with cervicofacial lesion
Clinical trials : 22 / Drugs : 27 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04921722 (ClinicalTrials.gov) | October 22, 2021 | 6/6/2021 | Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies | Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies: a Randomized Controlled Trial | Kaposiform Hemangioendothelioma;Tufted Angioma;Superficial Vascular Anomalies;Superficial Lymphatic Malformations | Drug: Percutaneous sirolimus;Drug: Oral sirolimus | Children's Hospital of Fudan University | NULL | Recruiting | N/A | 18 Years | All | 75 | Phase 4 | China |